Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes

NCT00113893 is registered in ClinicalTrials.gov with Scios, Inc. as lead sponsor.

NCT NCT00113893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes
Lead sponsor
Scios, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
December 31, 2007
Enrollment
62 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow diseases, bone marrow neoplasms, hematologic diseases, myelodysplastic syndromes